Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Gamunex 10% · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| IV Gamunex 10% | DRUG | - |
Inclusion Criteria: * Adult (18 or older) with deficiency in one or more IgG subclasses with documented history of recurrent infections limited to upper or lower respiratory tract, urinary, and/or skin. Exclusion Criteria: * Patients with panhypogammaglobulinemia or selective IgA deficiency.
Gamunex 10% is used for IgG deficiency, a condition characterized by low levels of immunoglobulin G, which can lead to recurrent infections. It is being investigated as a treatment for patients with IgG subclass deficiency and recurrent infections.
Gamunex 10% is developed by Grifols, S.A., a biopharmaceutical company. The company is publicly traded under the ticker symbol GRFS.
Gamunex 10% is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 2 trial has been completed to evaluate its efficacy in patients with IgG subclass deficiency and recurrent infections.
Gamunex 10% has one completed clinical trial, identified as NCT00417573. This Phase 2 study, titled 'Efficacy of IgIv in Patients With IgG Subclass Deficiency and Recurrent Infections,' enrolled 10 participants in the United States. The trial was uncontrolled and not randomized or double-blinded.
Gamunex 10% falls under the therapeutic area of infectious disease. It is being studied for its potential to reduce recurrent infections in patients with IgG deficiency.